Results 41 to 50 of about 103,862 (301)

PARP inhibitors in ovarian cancer: evidence, experience and clinical potential

Therapeutic Advances in Medical Oncology, 2017
Inhibitors of poly(ADP-ribose) polymerase (PARP) are considered one of the most active and exciting new therapies for the treatment of ovarian cancer.
Tarra Evans, Ursula Matulonis
doaj   +1 more source

The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]

, 2007
Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM, Auernhammer CJ, Boulay A, Boulay A, Bousquet C, Burkhard Göke, Cao C, Christoph J. Auernhammer, Enrico N. De Toni, Faivre S, Gerald Spöttl, Grewe M, Heinrich H.D. Meyer, Hosoi H, Jeng YJ, Jennifer Meinecke, Kathrin Zitzmann, Kawamata S, Kirchner GI, Luo J, O?Reilly KE, Oberg K, Ramage JK, Sawyers CL, Shah T, Shaw RJ, Stephan Brand, Sun SY, Vignot S, von Wichert G, Wang L, Wanner K, Wendel HG, Wullschleger S, Yao JC, Yee KW   +35 more
core   +1 more source

PARP Inhibitors for Chemoprevention—Letter [PDF]

Cancer Prevention Research, 2014
We read with great optimism To and colleagues' ([1][1]) article about PARP inhibitors as effective chemopreventive strategy for treating homologous repair (HR)–deficient tumors. Their overarching conclusion stated in the discussion is that “…synthetic lethality (i.e., PARP inhibitor ...
Saswati N, Chand, Fernando F, Blanco, Masaya, Jimbo, Theodore N, Tsangaris, Massimo, Cristofanilli, Charles J, Yeo, Jordan M, Winter, Michael J, Pishvaian, Jonathan R, Brody   +8 more
openaire   +2 more sources

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Frontiers in Pharmacology, 2021
Background: Poly(ADP-ribose) polymerase (PARP) inhibitors have breakthrough designations for metastatic castration-resistant prostate cancer (mCRPC). We performed a meta-analysis of current clinical trials to evaluate the efficacy of PARP inhibitors in ...
Kan Wu, Jiayu Liang, Yanxiang Shao, Sanchao Xiong, Shuyang Feng, Xiang Li   +5 more
doaj   +1 more source

Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. [PDF]

, 2014
Poly (ADP-ribose) polymerase 1 (PARP-1) is a constitutive enzyme, the major isoform of the PARP family, which is involved in the regulation of DNA repair, cell death, metabolism, and inflammatory responses.
Boulares, A.H., Cao, Z., Erdelyi, K., Gao, B., Hamdaoui, N., Haskó, G., Holovac, E., Horváth, B., Lafdil, F., Liaudet, L., Mukhopadhyay, P., Pacher, P., Park, O., Rajesh, M., Szabo, C., Wang, H., Wang, Y.   +16 more
core   +1 more source

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source

Evaluation of melanin-targeted radiotherapy in combination with radiosensitizing drugs for the treatment of melanoma [PDF]

, 2014
The incidence of malignant melanoma is rising faster than that of any other cancer in the United States. An [131I]-labeled benzamide - [131I]MIP-1145 - selectively targets melanin, reduces melanoma tumor burden and increases survival in preclinical ...
Babich, John, Boyd, Marie, Hutchison, Sharon, Mairs, Robert, Rae, Colin, Tesson, Mathias   +5 more
core   +1 more source

Hyperosmotic stress induces PARP1‐mediated HPF1‐dependent mono(ADP‐ribosyl)ation

FEBS Letters, EarlyView.
Sorbitol‐induced hyperosmotic stress rapidly induces reversible mono(ADP‐ribosyl)ation (MARylation) on PARP1 without the signs of genotoxic signaling. We show that PARP1 autoMARylation is HPF1 dependent and forms hydroxylamine‐resistant O‐glycosidic linkages.
Anna Georgina Kopasz, Mihály Mérey, Rebeka Vásárhelyi, Ramóna Pék, Victor Imburchia, László Henn, Adrián Kószó, Nicholas D. Lakin, Ivan Ahel, Sébastien Huet, Ágnes Czibula, Gyula Timinszky   +11 more
wiley   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice

Медицинский совет, 2020
Germline BRCA1/2 mutations account for about 10% of all breast cancer. BRCA1/2 proteins are involved in homologous recombination - DNA double-strand break repair mechanism.
M. A. Frolova, E. V. Glazkova, M. B. Stenina   +2 more
doaj   +1 more source